Orgenesis' Transdifferentiation process is a platform technology that has potential application across hundreds of indications. The first indications the company is pursuing include insulin dependent diabetes and patients that have had a pancreatectomy, through the use of Autologous Insulin Producing ("AIP") cells that transforms the patient's own liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell, designed to provide long-term insulin independence.
The transdifferentiated liver cells have the capacity to secrete the produced insulin in a glucose-regulated manner in-vitro and in-vivo making it ideally suited for insulin dependent diabetes and patients that have undergone a pancreatectomy. Moreover, this treatment ameliorates hyperglycemia and maintains a stable body weight in diabetic mice.
We are actively exploring a number of other areas of development for our platform technology.